IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Maria A. Glucksmann, Rory A.J. Curtis, Fong-Ying Tsai, Martin R. Hodge,

Rachel E. Meyers, Kyle J. MacBeth, and Rajasekhar Bandaru

Application No.:

N/A

Group No.:

N/A

Filed:

February 19, 2004

Examiner:

N/A

For:

NOVEL 14275, 54420, 8797, 27439, 68730, 69112 AND 52908 MOLECULES

AND USES THEREFOR

Mail Stop Sequence Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

SUBMISSION OF "SEQUENCE LISTING," COMPUTER READABLE COPY, AND/OR AMENDMENT PERTAINING THERETO FOR BIOTECHNOLOGY INVENTION CONTAINING NUCLEOTIDE AND/OR AMINO ACID SEQUENCE

1. This submission accompanies the new application being filed concurrently herewith

IDENTIFICATION OF PERSON MAKING STATEMENT

2.	I, Jean M. Silveri							
	(type or print name	e of person si	gning below)					
;	state the following:							
	CONTINUE TION VINDED 1	ACED CEC	EVONO 10() 11 104					
	CERTIFICATION UNDER 3	37 C.F.R. SECT	TIONS 1.8(a) and 1.10*					
I here	eby certify that, on the date shown below, this correspon	ndence is being:						
		MAILING						
×	•	deposited with the United States Postal Service in an envelope addressed Mail Stop Sequence, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.						
	37 C.F.R. SECTION 1.8(a)		37 C.F.R. SECTION 1.10*					
	with sufficient postage as first class mail.	Œ	as "Express Mail Post Office to Addressee"					
			Mailing Label No. EV407135224US					
	TRA	NSMISSION						
	transmitted by facsimile to the Patent and Tradema	ark Office.						
		Signat	ture frankling					
Date:	: February 19, 2004	Sean	Hunziker					

*WARNING:Each paper or fee filed by "Express Mail" must have the number of the "Express Mail" mailing label placed thereon prior to mailing, 37 C.F.R. section 1.10(b). "Since the filing of correspondence under section 1.10 without the Express Mail mailing label thereon is an oversight that can be avoided by the exercise of reasonable care, requests for waiver of this requirement will not be granted on petition." Notice of Oct. 24, 1996, 60 Fed. Reg. 56,439, at 56,442.

(type or print name of person certifying)

Practitioner's Docket No. MPI04-002OMNIM

ITEMS BEING SUBMITTED

3. Su	ıbmit	ted herewith	is/are:				
A.	(x)	Each "S		' is assigned a	separate identifier a	sequence(s) in this as required in 37 C.F.	
В.	()				aims, wherein referenced in 37 C.F.R. Section	ence is made to the secon 1.821(d).	quence by
C.	(x)		=	-	ed for this application C.F.R. Sections 1.82	on in computer readab 21(e) and 1.824.	le form, in
D.	()				lance with 37 C.F.R. er application identifi	Section 1.821(e), the ied as follows:	computer
In re a _l Applic		ation of:			Group No.:		
Applic Filed: For:	ation	i NO			Examiner:		
		-	dable form(s) o ication as follows		other application c	corresponds to the	"Sequence
Comp	outer	Readable Fo	rm			"Sequence Io	lentifier"
(othe	r app	lication)				(this app	olication)
E.	(x)					submitted and each	computer
		readable cop	py are the same, a	as required in	37 C.F.R. Section 1.	.821(f).	
		` '		•	a person registered 37 C.F.R. Section 1	to practice before t .821(b).	he Office,

i idelitioner o Doeil	 	0.00	- 0111	11111			
- () -					 _		

Fractitioner's Docket No. MIF 104-0020 MINIM								
	F. () Because this submission is made in fulfilling the requirement under 37 C.F.R. Section 1.821(g), a statement that the submission includes no new matter.							
() Because the statement is not made by a person registered to practice before the Office, the statement is verified, as required in 37 C.F.R. Section 1.821(g).								
STATEMENT THAT "SEQUENCE LISTING" AND COMPUTER READABLE COPY ARE THE SAME AND/OR THAT PAPERS SUBMITTED INCLUDES NO NEW MATTER								
4. I hereby state:								
be transferred from a	A. [x] Each computer readable form submitted in this application, including those forms requested to be transferred from applicant's other application, is the same as the "Sequence Listing" to which it is indicated to relate.							
B. [] All papers accompanying this submission, or for which a request for transfer from applicants' other application, introduce no new matter.								
EXTENSION OF TERM								
5. The proceedings herein are for a patent application and the provisions of 37 C.F.R. Section 1.136 apply.								
(a) [] Applicant petitions for an extension of time under 37 C.F.R. Section 1.136 (fees: 37 C.F.R. Section 1.17(a)(1)-(4)) for the total number of months checked below:								
Extension	Fee for other than	Fee for						
(months)	small entity	small entity						
***************************************		Sitter Vitery						
() one month	\$ 110.00	\$ 55.00						
() two months	\$ 420.00	\$ 210.00						
() three months	\$ 950.00	\$ 475.00						
() four months	\$1,480.00	\$ 740.00						
		Fee <u>\$0.00</u>						
If an additional extension of time is required, please consider this a petition therefor.								
An extension for months has already been secured, and the fee paid therefor of solution is deducted from the total fee due for the total months of extension now requested.								
Extension fee due with this request \$0.00								

Practitioner's Docket No. MPI04-002OMNIM

OR

(b) [x] Applicant believes that no extension of term is required. However, this conditional petition is being made to provide for the possibility that applicant has inadvertently overlooked the need for a petition and fee for extension of time.

1	FEE PAYMENT					
6. [] Attached is a check in the sum of \$_	·					
[] Charge Account No. 501668 the A duplicate of this transmittal is attack						
F	EE DEFICIENCY					
8. [x] If any additional extension and/or fee is required, charge Account No. 501668.						
	AMALENDIM IN DISERBANA CÉLITICA I C. DIC					
February 19, 2004	MILLENNIUM PHARMAGEUTICALS, INC. By Jean M. Silveri					
	Attorney Agent for Applicant					
	Registration No. 39,030					
	40 Landsdowne Street					
	Cambridge, MA 02139					
	Telephone - 617-679-7336					

Facsimile - 617-551-8820